ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry and Biosample Repository

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01577251
Recruitment Status : Recruiting
First Posted : April 13, 2012
Last Update Posted : September 26, 2016
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:
The goal of this study is two-fold: to establish a tissue banking respository (defined as blood, urine, soft tissue, tumor specimen, and normal tissue from areas surrounding tumor specimens), and to prospectively assess health related quality of life (QOL) over time in patients with a pathologically confirmed diagnosis of neoplasia receiving radiotherapy or photodynamic therapy (PDT)

Condition or disease
Patients With Pathologically Confirmed Neoplasia That Have Been Selected for Definitive Photodynamic Therapy, Proton, or Photon Radiotherapy.

Study Type : Observational
Estimated Enrollment : 2500 participants
Time Perspective: Prospective
Official Title: Registry and Biosample Repository
Study Start Date : June 2008
Estimated Primary Completion Date : June 2018



Primary Outcome Measures :
  1. Health Assessments [ Time Frame: 10 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 89 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Donors will be between the ages of 18 and 89 with pathologically confirmed neoplasia that are selected for definitive photodynamic therapy, proton, photon radiotherapy

-Pediatric patients with pathologically confirmed neoplasia that have been selected for definitive radiotherapy may elect to participate in a pediatric arm of quality of life, provided that the proper processes of parental permission and assent have occurred.

Criteria

Inclusion Criteria:

  • Anyone age 18 and above with a cancer diagnosis
  • Able to sign consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01577251


Contacts
Contact: Jay Dorsey, MD, PhD 855-216-0098 PennCancerTrials@emergingmed.com
Contact: Susan Mazzoni 215-662-6083 susan.mazzoni@uphs.upenn.edu

Locations
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19004
Contact: Jay Dorsey, MD, PhD    855-216-0098    PennCancerTrials@emergingmed.com   
Principal Investigator: Jay Dorsey, MD, PhD         
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Principal Investigator: Jay Dorsey, MD, PhD Abramson Cancer Center of the University of Pennsylvania

Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01577251     History of Changes
Other Study ID Numbers: UPCC 11908
First Posted: April 13, 2012    Key Record Dates
Last Update Posted: September 26, 2016
Last Verified: September 2016